Bronchial hyperreactivity and cough due to angiotensin-converting enzyme inhibitors.
Seventeen patients using angiotensin-converting enzyme (ACE) inhibitors for hypertension were evaluated with baseline spirometry followed by determination of bronchial reactivity by challenge with methacholine. There were nine coughers and eight noncoughers in the study. Among the nine coughers, eight demonstrated bronchial hyperreactivity. Conversely, none of the noncoughers disclosed bronchial hyperreactivity. Eight of the nine coughers were rechallenged two to six months following cessation of ACE inhibitor therapy. Six of these eight showed persistent bronchial hyperreactivity. We conclude that cough is associated with the use of ACE inhibitors in patients with underlying bronchial hyperreactivity. The findings indicate caution in administration of ACE inhibitors in asthmatic patients and those with known bronchial hyperreactivity.
Kaufman
J
J
Department of Medicine, Medical College of Wisconsin, Milwaukee.
Casanova
J E
JE
Riendl
P
P
Schlueter
D P
DP
D001249:Asthma / Q000175:diagnosis; D001980:Bronchi / Q000187:drug effects*; D001985:Bronchial Provocation Tests; D002216:Captopril / Q000009:adverse effects*; D003371:Cough / Q000139:chemically induced*; D004656:Enalapril / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D008448:Maximal Expiratory Flow Rate; D016210:Methacholine Chloride; D008688:Methacholine Compounds; D008875:Middle Aged; D013147:Spirometry; D014797:Vital Capacity
D008688:Methacholine Compounds; D016210:Methacholine Chloride; D004656:Enalapril; D002216:Captopril